# Trulicity (dulaglutide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dulaglutide

> The next catalyst for Trulicity (dulaglutide), sponsored by ELI LILLY & Co (LLY), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Trulicity (dulaglutide) |
| Codes | LY2189265 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Type 2 Diabetes](https://sec-api.dev/indications/type-2-diabetes) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### February 21, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125469 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20200221, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TRULICITY (DULAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125469%22

### September 3, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125469 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20200903, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TRULICITY (DULAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125469%22

### November 17, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125469 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20221117, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product TRULICITY (DULAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125469%22

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06739122 (A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06739122

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06739122 (A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06739122

## Same indication

- [Icosema](https://sec-api.dev/pdufa/icosema) (NVO)
- [LY3457263](https://sec-api.dev/pdufa/ly3457263) (LLY)
- [Oral semaglutide](https://sec-api.dev/pdufa/oral-semaglutide) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dulaglutide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Trulicity (dulaglutide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dulaglutide

```bibtex
@misc{secapidev_pdufa_dulaglutide_20261116,
  title        = {Trulicity (dulaglutide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dulaglutide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dulaglutide_20261116","title":"Trulicity (dulaglutide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dulaglutide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
